Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
805actual
Sites
201
Countries
Australia, Belgium, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-05-05 | actual | When the study began enrolling |
| Primary completion | 2024-07-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2020-02-13 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-23 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Neoplasms
Interventions
- Drug: olaparib
- Biological: durvalumab
- Drug: durvalumab placebo
- Drug: olaparib placebo
- Drug: Carboplatin
- Drug: Paclitaxel
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments
measured At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-01-24 · 26.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-11-30 · 1.1 MB · SAP_001.pdf
Publications
- PMID 41943281 — linked by the registry
- PMID 40590327 — linked by the registry
- PMID 38431043 — linked by the registry
- PMID 37864337 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed